Innovations in staging of prostate cancer
Poster Session 66
-
Location:Room London, North Hall (Level 1)
-
Chairs:
-
Aims and objectives of this session This session will examine Innovations in prostate cancer staging, prognostic groups and lymph node identification.
- Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (*) are 3 minutes in length, followed by 3 minutes for discussion.
Institutes: 1Vita-Salute University San Raffaele, Dept. of Urology, Milan, Italy, 2Mayo Clinic, Dept. of Urology, Rochester, Minnesota, United States of America, 3University of Cologne, Dept. of Urology, Cologne, Germany, 4Ludwig-Maximilians-University Munich,, Dept. of Urology, Munich, Germany, 5University Hospitals Leuven, Urology, Dept of Development and Regeneration, Leuven, Belgium, 6University Hospital Schleswig Holstein, Dept. of Urology and Pediatric Urology, Campus Kiel, Germany, 7Catherine & Joseph Aresty Department of Urology, Keck School of Medicine, University of Southern Cal, USC Institute of Urology, Los Angeles, California, United States of America, 8Phoenix Imaging Center, Dept. of Urology, Phoenix, Arizona, United States of America, 9OLV Ziekenhuis Aalst, Belgium ORSI Academy, Dept. of Urology, Melle, Belgium
Institutes: 1Klinikum rechts der Isar der Technischen Universität München, Dept. of Urology, Munich, Germany, 2Klinikum rechts der Isar der Technischen Universität München, Dept. of Nuclear Medicine, Munich, Germany
Institutes: 1Medical Center, University of Freiburg, Faculty of Medicine, Dept. of Urology, Freiburg, Germany, 2Medical Center, University of Freiburg, Faculty of Medicine, Dept. of Nuclear Medicine, Freiburg, Germany, 3Medical Center, University of Freiburg, Faculty of Medicine, Institute for Pathology, Freiburg, Germany
Institutes: 1Klinikum Rechts Der Isar, Technical University of Munich (TUM), Dept. of Urology, Munich, Germany, 2Klinikum Rechts Der Isar, Technical University of Munich (TUM), Dept. of Pathology, Munich, Germany, 3McGill University, Dept. of Family Medicine, Montreal, Canada
Institutes: 1San Luigi Hospital, Dept. of Urology, Turin, Italy, 2San Giovanni Battista Hospital, Dept. of Nuclear Medicine, Turin, Italy, 3San Luigi Hospital, Dept. of Radiology, Turin, Italy, 4IRCC Candiolo, Dept. of Radiology, Turin, Italy, 5Mauriziano Hospital, Dept. of Radiology, Turin, Italy
Institutes: 1Tokyo Medical and Dental University Graduate School, Dept. of Urology, Tokyo, Japan, 2Ochanomizu Surugadai Clinic, Dept. of Radiology, Tokyo, Japan
Institutes: 1University of Cambridge, Academic Urology Group, Dept. of Surgery, Cambridge, United Kingdom, 2Addenbrookes Hospital, Dept. of Urology, Cambridge, United Kingdom, 3Umea University, Dept. of Surgical and Perioperative Science, Umea, Sweden, 4Institute of Population Health, Manchester, United Kingdom, 5Singapore General Hospital, Dept. of Urology, Singapore, Singapore
Institutes: 1University of Cambridge, Academic Urology Group, Dept. of Surgery, Cambridge, United Kingdom, 2Addenbrookes Hospital, Dept. of Urology, Cambridge, United Kingdom, 3Umea University, Dept. of Surgical and Perioperative Science, Umea, Sweden, 4University of Manchester, Institute of Population Health, Manchester, United Kingdom
Institutes: 1Eberhard-Karls-University, Dept. of Urology, Tübingen, Germany, 2Qiagen, Dept. of Reasearch and Development, Hilden, Germany, 3Qiagen, Dept. of Research and Development, Hilden, Germany
Institutes: 1Regional Cancer Centre Uppsala/örebro, Dept. of Surgical Sciences, Uppsala, Sweden, 2King’s College London, Faculty of Life Sciences and Medicine, Division of Cancer Studies, London, United Kingdom, 3IRCCS Ospedale San Raffaele, Division of Experimental Oncology/Unit of Urology; URI, Milan, Italy, 4Uppsala University, Dept. of Surgical Sciences, Uppsala, Sweden
Institutes: 1Vita-Salute University San Raffaele, Dept. of Urology, Milan, Italy, 2Martini-Klinik Prostate Cancer Center, Dept. of Urology, Hamburg, Germany, 3Advanced Urotechnology Center, Scientific Institute “Istituto Auxologico Italiano, Dept. of Urology, Milan, Italy
Institutes: 1University Hospital Zurich, Dept. of Urology, Zurich, Switzerland, 2University Hospital Zurich, Dept. of Pathology and Molecular Pathology, Zurich, Switzerland, 3Moffitt Cancer Center, Dept. of Epidemiology, Tampa, United States of America, 4Harvard T.H. Chan School of Public Health, Dept. of Epidemiology, Boston, United States of America, 5Boston University, Dept. of Epidemiology, Boston, United States of America, 6Brigham and Women’s Hospital/Harvard Medical School, Channing Division of Network Medicine, Dept. of Medicine, Boston, United States of America, 7S. Orsola-Malpighi Hospital, Addarii Institute, Dept. of Pathology, Bologna, Italy, 8Dana-Farber Cancer Institute, Harvard Medical School, Dept. of Medical Oncology, Boston, United States of America